Patient adherence: A blind spot in cost-effectiveness analyses?

American Journal of Managed Care

Volumn 15, Issue 9, 2009, Pages 626-632

  Rosen, Allison B ^a   Spaulding, Alicen B ^b   Greenberg, Dan ^c   Palmer, Jennifer A ^d   Neumann, Peter J ^d  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^d TUFTS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; PRESCRIPTION DRUG;

ANTICOAGULATION; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COST EFFECTIVENESS ANALYSIS; HEALTH CARE COST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NEUROLOGIC DISEASE; PATIENT COMPLIANCE; PRIORITY JOURNAL; RISK REDUCTION; SELF CONCEPT; SELF MEDICATION; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW; COMPARATIVE STUDY; COST BENEFIT ANALYSIS; DRUG SELF ADMINISTRATION; ECONOMICS; MEDICATION COMPLIANCE; RANDOMIZATION; REGISTER; STATISTICAL MODEL; THEORETICAL MODEL; UNITED STATES;

COST-BENEFIT ANALYSIS; HUMANS; LOGISTIC MODELS; MEDICATION ADHERENCE; MODELS, THEORETICAL; PRESCRIPTION DRUGS; RANDOM ALLOCATION; REGISTRIES; SELF ADMINISTRATION; UNITED STATES;

EID: 70349425843     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. National Council on Patient Information and Education. Enhancing Prescription Medicine Adherence: A National Action Plan. August 2007. http://www.talkaboutrx.org/documents/enhancing-prescription-medicine-adherence. pdf. Accessed January 19, 2007.
2. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353(5):487-497.
3. Rizzo JA, Simons WR. Variations in compliance among hypertensive patients by drug class: implications for health care costs. Clin Ther. 1997;19(6):1446-1457.
4. McDonald HR Garg AX, Haynes RB. Interventions to enhance patient adherence to medication prescriptions: scientific review [published correction appears in JAMA. 2003;289(24):3242]. JAMA. 2002;288(22):2868-2879.
5. Cramer JA. A systematic review of adherence with medications for diabetes. Diabetes Care. 2004;27(5):1218-1224. (Pubitemid 38579798)
6. McDonnell PJ, Jacobs MR. Hospital admissions resulting from preventable adverse drug reactions. Ann Pharmacother. 2002;36(9): 1331-1336. (Pubitemid 34925265)
7. Rasmussen JN, Chong A, Alter DA. Relationship between adherence to evidence-based pharmacotherapy and long-term mortality after acute myocardial infarction. JAMA. 2007;297(2):177-186. (Pubitemid 46089734)
8. Sokol MC, McGuigan KA, Verbrugge RR, Epstein RS. Impact of medication adherence on hospitalization risk and healthcare cost. Med Care. 2005;43(6):521-530.
9. McCombs JS, Nichol MB, Newman CM, Sclar DA. The costs of interrupting antihypertensive drug therapy in a Medicaid population. Med Care. 1994;32(3):214-226.
10. Mar J, Rodriguez-Artalejo F. Which is more important for the efficiency of hypertension treatment: hypertension stage, type of drug or therapeutic compliance? J Hypertens. 2001;19(1):149-155.
11. Hughes DA, Bagust A, Haycox A. Walley T. The impact of non-compliance on the cost-effectiveness of pharmaceuticals: a review of the literature. Health Econ. 2001;10(7):601-615. (Pubitemid 32998372)
12. Hughes DA, Bagust A, Haycox A. Walley T. Accounting for non- compliance in pharmacoeconomic evaluations. Pharmacoeconomics. 2001;19(12):1185-1197. (Pubitemid 34074782)
13. Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russell LB. Recommendations of the Panel on Cost-Effectiveness in Health and Medicine. JAMA. 1996;276(15):1253-1258. (Pubitemid 26337709)
14. Neumann PJ, Stone PW, Chapman RH, Sandberg EA, Bell CM. The quality of reporting in published cost-utility analyses, 1976-1997. Ann Intern Med. 2000;132(12):964-972.
15. Chapman RH, Stone PW, Sandberg EA, Bell C, Neumann PJ. A comprehensive league table of cost-utility ratios and a sub-table of "panel-worthy" studies. Med Decis Making. 2000;20(4):451-467.
16. Neumann PJ, Greenberg D, Olchanski NV, Stone PW, Rosen AB. Growth and quality of the cost-utility literature, 1976-2001. Value Health. 2005;8(1):3-9.
17. Office of Health Economics and the International Federation of Pharmaceutical Manufacturers' Association. HEED: Health Economic Evaluations Database, 2007. October 29, 2007.
18. McGinn T, Wyer PC, Newman TB, Keitz S, Leipzig R, For GG; Evidence-Based Medicine Teaching Tips Working Group. Tips for learners of evidence-based medicine, 3: measures of observer variability (kappa statistic) [published correction appears in CMAJ. 2005; 173(1):18]. CMAJ. 2004;171(11):1369-1373.
19. Marchetti M, Pistorio A, Barosi G. Extended anticoagulation for prevention of recurrent venous thromboembolism in carriers of factor V Leiden - cost-effectiveness analysis [published correction appears in Thromb Haemost. 2000;84(6):1112]. Thromb Haemost. 2000;84(5):752-757.
20. Parker CS, Chen Z, Price M, et al. Adherence to warfarin assessed by electronic pill caps, clinician assessment, and patient reports: results from the IN-RANGE study. J Gen Intern Med. 2007;22(9):1254-1259. (Pubitemid 47247293)
21. Phillips KA, Shlipak MG, Coxson P, et al. Health and economic benefits of increased beta-blocker use following myocardial infarction. JAMA. 2000;284(21):2748-2754.
22. Clark WF, Churchill DN, Forwell L, Macdonald G, Foster S. To pay or not to pay? A decision and cost-utility analysis of angiotensin- converting-enzyme inhibitor therapy for diabetic nephropathy [published correction appears in CMAJ. 2000;162(7):973]. CMAJ. 2000;162(2):195-198. (Pubitemid 30073241)
23. Chernew ME, Rosen AB, Fendrick AM. Value-based insurance design. Health Aff (Millwood). 2007;26(2):w195-w203.
24. Rosen AB, Hamel MB, Weinstein MC, Cutler DM, Fendrick AM, Vijan S. Cost-effectiveness of full Medicare coverage of angiotensin- converting enzyme inhibitors for beneficiaries with diabetes. Ann Intern Med. 2005;143(2):89-99. (Pubitemid 41001419)
25. Choudhry NK, Avorn J, Antman EM, Schneeweiss S, Shrank WH. Should patients receive secondary prevention medications for free after a myocardial infarction? An economic analysis. Health Aff (Millwood). 2007;26(1):186-194.
26. Hughes D, Cowell W, Koncz T, Cramer J; International Society for Pharmacoeconomics and Outcomes Research Economics of Medication Compliance Working Group. Methods for integrating medication compliance and persistence in pharmacoeconomic evaluations. Value Health. 2007;10(6):498-509.
27. Boden WE, O'Rourke RA. Teo KK, et al; COURAGE Trial Research Group. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med. 2007;356(15):1503-1516.
28. Newby LK, LaPointe NM, Chen AY, et al. Long-term adherence to evidence-based secondary prevention therapies in coronary artery disease. Circulation. 2006;113(2):203-212. (Pubitemid 43754376)
29. Goldman DP, Joyce GF, Zheng Y. Prescription drug cost sharing: associations with medication and medical utilization and spending and health. JAMA. 2007;298(1):61-69. (Pubitemid 47026771)